SWP
KRYS icon

Stratos Wealth Partners’s Krystal Biotech KRYS Stock Holding History

Stratos Wealth Partners’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$377K Hold
1,459
– – ﹤0.01% 1196
2025
Q4 		$360K Buy
+1,459
New +$307K ﹤0.01% 1183

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Stratos Wealth Partners's KRYS Position: Q1 2026 in Review

Stratos Wealth Partners held its Krystal Biotech (KRYS) position steady in Q1 2026 at 1,459 shares worth $377K. The position accounts for ﹤0.01% of the portfolio, ranked #1196.

Stratos Wealth Partners first reported a position in KRYS in Q4 2025 and has held it in 2 quarters since. 367 funds tracked by Wall St. Rank hold KRYS as of Q1 2026.

  • Stratos Wealth Partners held 1,459 shares of Krystal Biotech worth $377K as of Q1 2026.
  • Stratos Wealth Partners left its Krystal Biotech share count unchanged in Q1 2026.
  • Krystal Biotech made up ﹤0.01% of Stratos Wealth Partners's portfolio in Q1 2026, its #1196 holding.
  • Stratos Wealth Partners first reported a position in Krystal Biotech in Q4 2025 and has held it in 2 quarters since.
  • 367 funds tracked by Wall St. Rank held Krystal Biotech as of Q1 2026.

Based on Stratos Wealth Partners's 13F filing for Q1 2026, filed 28 Apr 2026.